Cétuximab (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Cétuximab" in French language version.

refsWebsite

Global rank French rank

2ascopubs.org

low place

7,741^st place

2nejm.org

2,374^th place

298^th place

1qmul.ac.uk

1,735^th place

168^th place

1issn.org

57^th place

4^th place

1doi.org

2^nd place

3^rd place

1nature.com

234^th place

147^th place

1aacrjournals.org

8,869^th place

4,895^th place

1biomedcentral.com

2,747^th place

1,253^rd place

1sciencedirect.com

149^th place

80^th place

1springer.com

274^th place

223^rd place

1nih.gov

4^th place

12^th place

1wikipedia.org

low place

aacrjournals.org

mct.aacrjournals.org

(en) Li X, Lu Y, Liang K, Pan T, Mendelsohn J, Fan Z, « Requirement of hypoxia-inducible factor-1alpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab » Mol Cancer Ther. 2008;7:1207–1217

ascopubs.org

jco.ascopubs.org

(en) Baselga J, Trigo JM, Bourhis J. et al. « Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck » J Clin Oncol. 2005;23:5568–5577
(en) Vermorken JB, Trigo J, Hitt R. et al. « Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy » J Clin Oncol. 2007;25:2171–2177

biomedcentral.com

(en) Marechal R, De Schutter J, Nagy N. et al. « Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients » BMC Cancer. 2010;10:340

doi.org

dx.doi.org

(en) G Galizia, E Lieto, F De Vita et M Orditura, « Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer », Oncogene, vol. 26, n^o 25,‎ mai 2007, p. 3654–3660 (ISSN 0950-9232 et 1476-5594, DOI 10.1038/sj.onc.1210381, lire en ligne, consulté le 21 mai 2020)

issn.org

portal.issn.org

(en) G Galizia, E Lieto, F De Vita et M Orditura, « Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer », Oncogene, vol. 26, n^o 25,‎ mai 2007, p. 3654–3660 (ISSN 0950-9232 et 1476-5594, DOI 10.1038/sj.onc.1210381, lire en ligne, consulté le 21 mai 2020)

nature.com

(en) G Galizia, E Lieto, F De Vita et M Orditura, « Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer », Oncogene, vol. 26, n^o 25,‎ mai 2007, p. 3654–3660 (ISSN 0950-9232 et 1476-5594, DOI 10.1038/sj.onc.1210381, lire en ligne, consulté le 21 mai 2020)

nejm.org

Chung CH, Mirakhur B, Chan E et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose, N Engl J Med, 2008;358:1109-1117
Houchens N, Hartley S, Commins SP, Claar D, Saint S, Hunting for a Diagnosis, N Engl J Med, 2021; 384:462-467

nih.gov

ncbi.nlm.nih.gov

(en) Kumar SS, Price TJ, Mohyieldin O, Borg M, Townsend A, Hardingham JE, « KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model », Gastrointest Cancer Res, vol. 7, n^o 1,‎ 2014, p. 23-6. (PMID 24558511, PMCID PMC3930148) modifier

qmul.ac.uk

chem.qmul.ac.uk

Masse molaire calculée d’après « Atomic weights of the elements 2007 », sur www.chem.qmul.ac.uk.

sciencedirect.com

(en) Rodriguez J, Lee SC, Morgan S. et al. « Fc γ receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer » Eur J Cancer. 2012;48:1774–1780

springer.com

rd.springer.com

(en) Liu L, Cao Y, Tan A, Liao C, Gao F, « Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials » Cancer Chemother Pharmacol. 2010;65:849–861

wikipedia.org

fr.wikipedia.org

(en) Kumar SS, Price TJ, Mohyieldin O, Borg M, Townsend A, Hardingham JE, « KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model », Gastrointest Cancer Res, vol. 7, n^o 1,‎ 2014, p. 23-6. (PMID 24558511, PMCID PMC3930148) modifier